Vapotherm Management

Management criteria checks 2/4

Vapotherm's CEO is Joe Army, appointed in Jun 2012, has a tenure of 11.42 years. total yearly compensation is $3.87M, comprised of 14.8% salary and 85.2% bonuses, including company stock and options. directly owns 7.03% of the company’s shares, worth €1.02M. The average tenure of the management team and the board of directors is 2.9 years and 5 years respectively.

Key information

Joe Army

Chief executive officer

US$3.9m

Total compensation

CEO salary percentage	14.8%
CEO tenure	11.4yrs
CEO ownership	7.0%
Management average tenure	2.9yrs
Board average tenure	5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joe Army's remuneration changed compared to Vapotherm's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$69m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$108m
Dec 31 2022	US$4m	US$572k	-US$113m
Sep 30 2022	n/a	n/a	-US$110m
Jun 30 2022	n/a	n/a	-US$98m
Mar 31 2022	n/a	n/a	-US$72m
Dec 31 2021	US$3m	US$538k	-US$60m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$57m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$3m	US$433k	-US$52m
Sep 30 2020	n/a	n/a	-US$47m
Jun 30 2020	n/a	n/a	-US$47m
Mar 31 2020	n/a	n/a	-US$52m
Dec 31 2019	US$3m	US$400k	-US$51m
Sep 30 2019	n/a	n/a	-US$51m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$47m
Dec 31 2018	US$625k	US$300k	-US$43m
Sep 30 2018	n/a	n/a	-US$39m
Jun 30 2018	n/a	n/a	-US$37m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$545k	US$275k	-US$31m

Compensation vs Market: Joe's total compensation ($USD3.87M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.

CEO

Joe Army (59 yo)

11.4yrs

Tenure

US$3,874,994

Compensation

Mr. Joseph F. Army, also known as Joe, CPA has been the Chief Executive Officer and President of Vapotherm, Inc. since June 26, 2012. Mr. Army serves as Advisor of Physician 360, Inc. He served as the Chie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Joseph Army	CEO, President & Director	11.4yrs	US$3.87m	7.03% $ 1.0m
John Landry	Senior VP	11.3yrs	US$1.35m	0.71% $ 102.4k
Brian Lawrence	Senior VP & CTO	1.9yrs	US$1.44m	0.27% $ 39.0k
William Niland	Founder	no data	no data	no data
Dorota Mckay	VP, Controller & Chief Accounting Officer	1.9yrs	no data	0.057% $ 8.3k
Anthony Haagen	Vice President of Legal & Compliance	no data	no data	no data
James Lightman	Senior VP	2.9yrs	no data	no data
Lindsay Becker	Vice President of Human Resources	7.4yrs	no data	no data
Jessica Whittle	Chief Medical Officer & VP of Clinical Research	less than a year	no data	no data

2.9yrs

Average Tenure

51.5yo

Average Age

Experienced Management: VA20's management team is considered experienced (2.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Joseph Army	CEO, President & Director	11.4yrs	US$3.87m	7.03% $ 1.0m
James Liken	Independent Chairman of the Board	13.5yrs	US$104.24k	0.97% $ 140.8k
Elizabeth Weatherman	Independent Director	6.1yrs	US$74.24k	1.46% $ 212.1k
Anthony Arnerich	Independent Director	10.6yrs	US$66.74k	1.23% $ 177.9k
Lance Berry	Independent Director	3.8yrs	US$74.24k	0.26% $ 38.1k
Donald Spence	Independent Director	3.1yrs	US$74.24k	0.050% $ 7.3k
Lori Knowles	Independent Director	2.4yrs	US$61.74k	0.032% $ 4.6k
Mary Moynihan	Independent Director	2.4yrs	US$64.24k	0.037% $ 5.4k

5.0yrs

Average Tenure

61yo

Average Age

Experienced Board: VA20's board of directors are considered experienced (5 years average tenure).

Vapotherm Management

Management criteria checks 2/4

Key information

Recent management updates

Vapotherm, Inc., Annual General Meeting, Jun 21, 2022

Insider recently bought €4.0m worth of stock

Independent Chairman of the Board recently bought €141k worth of stock

Independent Director recently bought €91k worth of stock

Insider recently bought €180k worth of stock

Recent updates

Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADE

The New York Stock Exchange to Commence Delisting Proceedings against Vapotherm

Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023

Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023

Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023

Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Vapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023

Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum Requirement

Vapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Vapotherm, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Vapotherm, Inc. Provides Revenue Guidance for 2022

Vapotherm, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Vapotherm Announces NYSE Continued Listing Standard Notice

Vapotherm, Inc. Reports Unaudited Condensed Consolidated Impairment Charges for the Second Quarter Ended June 30, 2022

Vapotherm, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Vapotherm, Inc. Plans to Move All of Its Manufacturing Operations from New Hampshire to Mexico

Vapotherm, Inc.(NYSE:VAPO) dropped from Russell 2000 Growth Index

Vapotherm, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Vapotherm, Inc., Annual General Meeting, Jun 21, 2022

Vapotherm, Inc. Provides Revenue Guidance for the First Quarter of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vapotherm, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Vapotherm, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Vapotherm, Inc. Announces Revenue Guidance for the Fourth Quarter of 2021, Full Year 2021 and 2022

Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)

Chief Accounting Officer Joel Dube has left the company

Vapotherm, Inc. Revises Revenue Guidance for the Fiscal Year 2021

Vapotherm, Inc. Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform

Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.35 loss in 2Q 2020)

Insider recently bought €4.0m worth of stock

Independent Director Marina Hahn has left the company

Independent Chairman of the Board recently bought €141k worth of stock

First quarter 2021 earnings released: US$0.40 loss per share (vs US$0.66 loss in 1Q 2020)

Vapotherm, Inc. Provides Financial Guidance for 2021

Independent Director recently bought €91k worth of stock

New 90-day low: €19.10

Revenue beats expectations

Full year 2020 earnings released: US$2.16 loss per share (vs US$2.74 loss in FY 2019)

Vapotherm, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €28.00

Insider recently bought €180k worth of stock

Vapotherm, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year 2020

Third quarter 2020 earnings released: US$0.49 loss per share

Revenue beats expectations

Vapotherm, Inc. Not Provides Earnings Guidance for the Full Year 2020

Vapotherm, Inc. to Report Q2, 2020 Results on Aug 04, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age